307538-52-9

Upstream product

• 32084-59-6 6-bromoquinazolin-4(3H)-one 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 118-92-3 anthranilic acid 
• 32084-59-6 6-bromo-4-hydroxyquinazoline 
• 110-91-8 morpholine 
• 38267-96-8 6-bromo-4-chloroquinozoline 

Downstream Products

• 1093818-24-6 2,4-difluoro-N-(2-methoxy-5-(4-morpholinoquinazolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1093818-30-4 2-[({2-[({5-[4-(4-morpholinyl)-6-quinazolinyl]-3-pyridinyl}amino)sulfonyl]ethyl}amino)carbonyl]benzoic acid 
• 1404227-55-9 3-(4-fluorophenylsulfonamino)-2-methoxy-5-(4-morpholinoquinazolin-6-yl)benzamide 
• 1404227-60-6 3-(4-fluorophenylsulfonamino)-5-(4-morpholinoquinazolin-6-yl)benzamide 
• 1404227-62-8 3-(4-chlorophenylsulfonamino)-5-(4-morpholinoquinazolin-6-yl)benzamide 
• 1404227-57-1 3-(4-chlorophenylsulfonamino)-2-methoxy-5-(4-morpholinoquinazolin-6-yl)benzamide 
• 1404227-58-2 3-(4-methylphenylsulfonamino)-2-methoxy-5-(4-morpholinoquinazolin-6-yl)benzamide 
• 1404227-79-7 3-(2,4-difluorophenylsulfonamino)-2-methoxy-5-(4-morpholinoquinazolin-6-yl)benzamide 
• 1404227-73-1 3-cyclopropylsulfonamino-2-methoxy-5-(4-morpholinoquinazolin-6-yl)benzamide 
• 1579281-61-0 N-methyl-3-(4-fluorophenylsulfonamino)-2-methoxy-5-(4-morpholinoquinazolin-6-yl)benzamide 
• 1579281-62-1 N,N-dimethyl-3-(4-fluorophenylsulfonamino)-2-methoxy-5-(4-morpholinoquinazolin-6-yl)benzamide 
• 1579281-63-2 methyl 3-(4-fluorophenylsulfonamino)-2-methoxy-5-(4-morpholinoquinazolin-6-yl)benzoate 
• 1404227-71-9 2-chloro-3-(4-fluorophenylsulfonamino)-5-(4-morpholinoquinazolin-6-yl)benzamide 

Relevant academic research and scientific papers

UiO-66-NH2as an effective solid support for quinazoline derivatives for antibacterial agents against Gram-negative bacteria

Nanomaterials have been widely used as a class of antibacterial drugs. However, the bottlenecks of this class of materials are their significant aggregation and accumulation, as well as toxicity resulting from excessive metal leaching. Metal-organic frameworks (MOFs) have inspired researchers owing to their distinct characteristics of robust architecture and tunable pore structures, which may help overcome the above challenges. We, herein, synthesize UiO-66-NH2 and use it as a solid support for loading quinazoline derivatives that are specifically designed and active against Gram-negative bacteria. The quinazoline derivatives were adsorbed on UiO-66-NH2 nanoparticles to form new UiO-66-NH2-quinazoline formulations which have a large inhibitory zone against Gram-negative bacteria, compared to that of free quinazoline compounds. This work has the potential for increasing antibacterial activity while also broadening the antibacterial range, and thus opens a pathway for new medical applications using MOFs. This journal is

Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere

2-Substituted-3-sulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides have been proposed as novel structures of PI3K inhibitors and anticancer agents based on bioisostere. In the present study, 2-substituted-3-sulfonamino-5-(4- morpholinoquinazolin-6-yl)benzamides and 2-methoxy-3-sulfonamino-5-(4- morpholinoquinolin-6-yl)benzamides were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against four human cancer cell lines, including A549, HCT-116, U-87 MG and KB. The SAR of the title compounds was preliminarily discussed. Compound 1a with potent antiproliferative activity was tested for its inhibitory activity against PI3K and mTOR and its effect on the AKT and p-AKT473. The anticancer effect of 1a was evaluated in established nude mice U-87 MG xenograft model. The results suggest that compound 1a can significantly inhibit PI3K/AKT/mTOR pathway and tumor growth. These findings strongly support the assumption that title compounds are potent PI3K inhibitors and anticancer agents.

QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of P13 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.

THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, ne

NOVEL CHEMICAL COMPOUNDS

This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.